FDA Approves Casgevy for Young Children with Sickle Cell Disease
The FDA has granted supplemental approval for Casgevy for young children with sickle cell disease and transfusion-dependent β thalassemia.
Asset / Drug
Drug and asset intelligence for Casgevy with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Gene Therapy
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.